
|Videos|May 19, 2017
Results of the ZUMA-1 Trial Exploring KTE-C19 in NHL
Author(s)Sattva S. Neelapu, MD
Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
2
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
3
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
4
First Patient Is Dosed in Trial of HLX-4310 for Relapsed/Refractory Osteosarcoma
5




























